Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
Michaela WaibelJohn M WentworthMichelle SoJennifer J CouperFergus J CameronRichard J MacIsaacGabby AtlasAlexandra GorelikSara LitwakLaura Sanz-VillanuevaPrerak TrivediSimi AhmedFrancis J MartinMadeleine E DoyleJessica E HarbisonCandice HallBalasubramanian KrishnamurthyPeter G ColmanLeonard C HarrisonHelen E ThomasThomas W H Kaynull nullPublished in: The New England journal of medicine (2023)
In patients with type 1 diabetes of recent onset, daily treatment with baricitinib over 48 weeks appeared to preserve β-cell function as estimated by the mixed-meal-stimulated mean C-peptide level. (Funded by JDRF International and others; BANDIT Australian New Zealand Clinical Trials Registry number, ACTRN12620000239965.).